Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus nab-paclitaxel as second-line treatment for advanced esophageal squamous cell carcinoma
ChiCTR2400085451Phase 4Completed
- Sponsor
- Shandong Cancer Hospital
- Start
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of camrelizumab and paclitaxel in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: Progression-free survival. Started Jun 2024; status: completed.
02
Drugs
camrelizumabpaclitaxel
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2400085451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085451.